rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CBIO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Crescent Biopharma earnings missed by $0.23, revenue topped estimates
      Nov 13Investing.comCBIO
      Crescent Biopharma: Q3 Earnings Snapshot
      Nov 12Yahoo FinanceCBIO
      Crescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
      Nov 12Yahoo FinanceCBIO
      Crescent Biopharma Announces Grants of Inducement Awards
      Nov 3Yahoo FinanceCBIO
      H.C. Wainwright reiterates Crescent Biopharma stock rating at buy
      Oct 19Investing.comCBIO
      Stifel reiterates Crescent Biopharma stock rating on pipeline progress
      Oct 16Investing.comCBIO
      Crescent Biopharma advances cancer drug trials across portfolio
      Oct 15Investing.comCBIO
      Crescent Biopharma Announces Grants of Inducement Awards
      Oct 6Yahoo FinanceCBIO
      Stifel reiterates Buy on Crescent Biopharma stock, $28 target
      Oct 6Investing.comCBIOSF
      Crescent Biopharma stock rating upgraded to buy at H.C. Wainwright
      Oct 6Investing.comCBIO
      HC Wainwright Upgrades Crescent Biopharma to Buy From Neutral, Price Target is $36
      Oct 6Yahoo FinanceCBIO
      Crescent Biopharma's Investigational New Drug Application for CR-002 to Treat Solid Tumors Cleared by FDA
      Oct 5Yahoo FinanceCBIO
      Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
      Oct 5Yahoo FinanceCBIO
      The Nascent Crescent Biopharma Thesis: One Year Later And Things Are Steady (NASDAQ:CBIO)
      Sep 25Seeking AlphaCBIO
      Crescent Biopharma Announces Grants of Inducement Awards
      Sep 25Yahoo FinanceCBIO
      Wedbush Remains a Buy on Crescent Biopharma (CBIO)

      Detailed price information for Crescent Biopharma Inc (CBIO-Q) from The Globe and Mail including charting and trades.

      Sep 15The Globe and MailCBIO
      Crescent Biopharma at Morgan Stanley conference: pipeline bets build
      Sep 14Investing.comCBIOMS
      Crescent Biopharma at Cantor conference: global trial push
      Sep 10Investing.comCBIO
      Crescent Biopharma Announces Grants of Inducement Awards
      Sep 9Yahoo FinanceCBIO
      Crescent Biopharma to Present at September Investor Conferences

      WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in September: 2026 Cantor Global Healthcare Conference, fireside chat on Thursday, September 10, 2026 at 1:35 p.m. ET in New York.Morgan Stanley 24th Annual Global He

      Sep 3Yahoo FinanceCBIO

      This is the newest page. Registered accounts read further back.